Einstein Proved Matter Is Energy. A Florida Doctor Asks Why Medicine Has Never Measured Yours.

Psychiatrist Dr. Fenton G. LeBon launched the Human Energy Center, a proposed framework that treats human energy as an integrated physiological output across six domains. The framework has not been evaluated in published clinical studies; its rationale cites a study in which 13.6% of 686 primary-care patients reported fatigue and a 2021 review describing age-related NAD+ declines across multiple organisms.

Analysis

This is a founder-led positioning exercise, not yet a clinical or commercial inflection. The investable question is whether the framework can move from a branded concept and treatment protocol to validated measurements, reproducible outcomes, and reimbursable care. Until then, claims around nano-delivered NAD+ and peptides should not be treated as evidence of efficacy or durable demand; the cited background on age-related NAD+ changes does not establish benefit from this protocol. There is no identified public issuer or demonstrated revenue exposure, so near-term read-through to healthcare equities is negligible.

If the model gains traction, the second-order opportunity would be in validated diagnostics and longitudinal care platforms, while supplement and wellness providers could face higher evidence expectations. The corresponding downside is regulatory and reputational: therapeutic claims or peptide delivery could attract scrutiny, and weak outcomes would undermine the broader “energy medicine” category. Over 1–3 months, watch for peer-reviewed protocol data, named clinical partners, and a clearly defined product and regulatory pathway. Over 6–18 months, adoption depends on independent replication, safety, durable patient-reported or objective benefit, and willingness to pay or reimbursement. The contrarian point is that fatigue is a real care gap, but naming a discipline does not create a defensible market; measurement and outcomes—not the framework—would be the moat.

Key Decisions for Investors

• No trade on this release: no listed company is identified, and there is no independently established efficacy, adoption, or financial impact.
• Treat any exposure to NAD+ supplements, peptide services, or wellness platforms as an alert rather than a thesis. Reassess only if independent clinical results, a credible regulatory pathway, and evidence of paid demand emerge.
• Key falsifiers for a future bullish thesis: failure to publish controlled outcomes, safety or regulatory concerns around the protocol, or no evidence of repeat use and willingness to pay within 6–18 months.